Atara Biotherapeutics (LTS:0HIY) Cash-to-Debt : 0.89 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Atara Biotherapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.89.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Atara Biotherapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Atara Biotherapeutics's Cash-to-Debt or its related term are showing as below:

LTS:0HIY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.89 Med: 280.4 Max: No Debt
Current: 0.89

During the past 12 years, Atara Biotherapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.89. And the median was 280.40.

LTS:0HIY's Cash-to-Debt is ranked worse than
78.83% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs LTS:0HIY: 0.89

Atara Biotherapeutics Cash-to-Debt Historical Data

The historical data trend for Atara Biotherapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Atara Biotherapeutics Cash-to-Debt Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

16.49

33.32

13.13

3.39

0.89

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.39	3.74	2.37	1.66	0.89

Competitive Comparison of Atara Biotherapeutics's Cash-to-Debt

For the Biotechnology subindustry, Atara Biotherapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cash-to-Debt falls into.

Atara Biotherapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Atara Biotherapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	51.725	/	(12.179	+	45.693)
	=	0.89

Atara Biotherapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	51.725	/	(12.179	+	45.693)
	=	0.89

Atara Biotherapeutics (LTS:0HIY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Atara Biotherapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (LTS:0HIY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ATRA:USA AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (LTS:0HIY) Headlines

No Headlines